CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2012

    CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2012

PR Newswire

ATLANTA, Nov. 19, 2012

ATLANTA, Nov. 19, 2012 /PRNewswire/ --CryoLife, Inc. (NYSE: CRY), a leading
tissue processing and medical device Company focused on cardiac and vascular
surgery, announced today that its Board of Directors has approved a quarterly
cash dividend for the fourth quarter 2012 of $0.025 per share of common stock
outstanding. The quarterly cash dividend of $0.025 per share will be paid on
December 21, 2012 to all common stockholders of record as of December 14,
2012. The ex-dividend date for the quarterly dividend is December 12, 2012.

CryoLife anticipates paying quarterly dividends in March, June, September, and
December of each year. Based on the number of shares currently outstanding,
the Company expects to pay a total annual dividend of approximately $2.7
million. These statements represent management's current beliefs and
expectations and are forward looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. As such, they are subject to
risks and uncertainties that could cause future events to deviate from current
expectations, including without limitation that the declaration of future
dividends and the establishment of the per share amount, record dates, and
payment dates for future dividends are subject to final determination by the
Company's Board of Directors, and will be dependent upon future earnings, cash
flows, financial requirements, the Board's evaluation of competing uses for
available cash, and other factors.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution
of implantable living human tissues for use in cardiac and vascular surgeries
throughout the U.S., certain countries in Europe, and Canada.CryoLife's
CryoValve^® SG pulmonary heart valve, processed using CryoLife's proprietary
SynerGraft^® technology, has FDA 510(k) clearance for the replacement of
diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary
valves. CryoLife's CryoPatch^® SG pulmonary cardiac patch has FDA 510(k)
clearance for the repair or reconstruction of congenital heart
defects.CryoLife's BioGlue^® Surgical Adhesive is FDA approved as an adjunct
to sutures and staples for use in adult patients in open surgical repair of
large vessels.BioGlue is also CE marked in the European Community for use in
soft tissue repair and is approved in Japan for use in the repair of aortic
dissections.Additional marketing approvals for BioGlue have been granted in
several other countries throughout the world. CryoLife, through its subsidiary
Cardiogenesis Corporation, specializes in the treatment of coronary artery
disease for severe angina using a laser console system and single use,
fiber-optic handpieces to perform a surgical procedure known as
Transmyocardial Revascularization (TMR). In addition, CryoLife's subsidiary
Hemosphere, Inc. markets the HeRO^® Graft, which is a solution for end-stage
renal disease in certain hemodialysis patients. CryoLife distributes
PerClot^®, an absorbable powder hemostat, in the European Community and other
select international countries.CryoLife's BioFoam^™ Surgical Matrix is CE
marked in the European Community for use as an adjunct in the sealing of
abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by
ligature or other conventional methods is ineffective or impractical.

For additional information about CryoLife, visit CryoLife's website,

CryoLife                                         The Ruth Group
D. Ashley Lee                                    Nick Laudico / Zack Kubow
Executive Vice President, Chief Financial Officer 646-536-7030 / 7020
and Chief Operating Officer             
Phone: 770-419-3355                     

SOURCE CryoLife, Inc.

Press spacebar to pause and continue. Press esc to stop.